LQDA - Liquidia Corporation
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.
As of Nov 13, 2026: spot at $57.77, ATM IV 64.5%, max pain $40.00, GEX (assumed dealer book) $663.3K of delta per 1% move.
Exposures are the assumed dealer book over the expirations within 30 days of the session, or the first four when none are (4 expirations, through Dec 11, 2026), as of Nov 13, 2026. Assumes dealers are long the calls and short the puts, a share p of open interest each - here 100% of open interest (the GEX page sets the share). A date without a stored exposure is a gap; a value marked * is partial, averaged over fewer days, or may include contracts expiring that day or of an unreadable expiration: its reason is printed beside it.
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Market Cap
- $5.17B
- Beta
- 0.54
- 52-Week Range
- 22.31-93.61
- CEO
- Roger A. Jeffs
- Employees
- 216
- IPO Date
- Jul 26, 2018
- Exchange
- NASDAQ
What LQDA Looks Like to Options Traders Today
IV rank of 0.0% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); the assumed dealer book's GEX is positive ($663.3K of delta per 1% move): its hedging leans against the trend, damping realized volatility where real dealers are positioned like the book; the 25-delta skew (0.045) prices calls richer than puts, often reflecting upside speculation or squeeze risk.
What This Page Covers
The LQDA overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked LQDA overview questions
- What is LQDA?
- LQDA is the ticker symbol for Liquidia Corporation, a listed security. Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Listed on NASDAQ. LQDA is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the LQDA options snapshot look like today?
- As of Nov 13, 2026, the LQDA options snapshot shows spot at $57.77, ATM IV 64.5%, IV rank 0.0%, max pain $40.00, GEX (assumed dealer book) $663.3K of delta per 1% move, expected move 18.48%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, the assumed dealer book's gamma exposure and the put-minus-call delta balance, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are LQDA's key statistics?
- Liquidia Corporation (LQDA) carries a market capitalization of $5.17B, beta of 0.54 relative to the broader market, 52-week range of 22.31-93.61. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does LQDA belong to?
- Liquidia Corporation operates in the Healthcare sector, in the Medical - Pharmaceuticals industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare LQDA's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the LQDA data on this page?
- The options snapshot above is dated Nov 13, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, twice-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).